Cero Therapeutics Holdings, Inc.
CERO- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001870404
No open-market purchases or sales by Cero Therapeutics Holdings, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesCEROW
13F holders, Q4 2025
Institutional positions in Cero Therapeutics Holdings, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 0
- −11 vs. Q3 2025
- Shares held
- 0
- −157.0K (−100.0%) vs. Q3 2025
- Total value
- $0
- −$798.7K (−100.0%) vs. Q3 2025
- New holders
- 0
- 0 more added
- Sold out
- 11
- 0 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CERO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 11 | $798.7K |
| Q2 2025 | 8 | $2.38M |
| Q1 2025 | 15 | $527.7K |
| Q4 2024 | 21 | $800.3K |
| Q3 2024 | 18 | $320.0K |
| Q2 2024 | 15 | $557.1K |
| Q1 2024 | 9 | $4.85M |
| Q4 2023 | 10 | $7.49M |
| Q3 2023 | 10 | $7.33M |
| Q2 2023 | 13 | $10.6M |
| Q1 2023 | 17 | $12.5M |
| Q4 2022 | 46 | $101.1M |
| Q3 2022 | 66 | $153.0M |
| Q2 2022 | 54 | $144.5M |
| Q1 2022 | 45 | $137.2M |
| Q4 2021 | 36 | $104.2M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Cero Therapeutics Holdings, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −121,000−100.0% | Sold out |
| ARCH Venture Management, LLC | 0 | $0 | 0.00% | −22,389−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −10,244−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,299−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −1,050−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −968−100.0% | Sold out |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| Jones Financial Companies LLLP | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −1−100.0% | Sold out |